“The severe patients given SOC who advance to critical, may be just as likely to die as those who were critical when they entered the trial and were started on SOC (placebo). So, was severe data not included in the PR because the data was bad, or because the data needs further analysis?”

Great point. I figure they have analyzed both populations by now, but maybe the larger cohort of sever patients (322) is taking longer to complete. If leronlimab could prove a stat sig reduction in progression from severe to critical, that would good enough for EUA. Let’s see what Monday morning brings.